(e) a C7-20 aralkyl which may have a substituent, (f) a carbamoyl which may have 1 or 2 substituent(s) selected from the group consisting of (i) a C3-6 cycloalkyl which may have a substituent, (ii) a C6-14 aryl which may have a substituent, (iii) a C7-20 aralkyl which ...
gene-deficient Chinese hamster cell CHO (hereinafter simply referred to as CHO (dhfr−) cell), mouse L cell, mouse AtT-20, mouse myeloma cell, mouse ATDC5 cell, mouse NS0 cell, mouse FM3A cell, rat GH3 cell, human FL cell, human embryonic HEK293 cell, human embryonic 293F cell, ...
wherein the formulation is lyophilized from a liquid formulation comprising (a) 0.05 mg/ml to 10.0 mg/ml ADAMTS13; (b) 0 mM to 200 mM of a pharmaceutically acceptable salt; (c) 0.5 mM to 20 mM calcium; (d) a sugar and/or sugar alcohol; (e) a nonionic surfactant; and (f) a ...
(f) a cyano group, (g) a nitro group, (h) a hydroxyl group, (i) C1-6 alkoxy-carbonyl (particularly methoxycarbonyl), (j) carbamoyl group, (k) C1-6 alkyl-carbonyl-amino (particularly acetylamino), (l) C1-6 alkylthio (particularly methylthio), (m) C6-10 aryl-C1-6 alkoxy (...
(f) an optionally substituted C6-14 aryloxy group (the C6-14 aryloxy group is optionally substituted by substituent(s) such as a halogen atom, hydroxy, cyano, amino, optionally halogenated C1-6 alkyl, mono- or di-C1-6 alkylamino, mono- or di-C6-14 arylamino, mono- or di-C7-16 aral...
Adams et al: “The role of viscosupplementation with hylan G-F 20 (Synvisc(R)) in the treatment of osteoarthritis of the knee: a Canadian multicenter trial comparing hylan G-F 20 alone, hylan G-F 20 with non-steroidal anti-inflammatory drugs (NSAIDs)and NSAIDs alone”, Osteoarthritis and...
BR_si = BR4_si ⨯ BR ∑ i = 0 n BR4_si ⨯ FNUM_si FNUM ( 12 ) The target bit rate BRsi in the scene si determined in this way is, in place of the target bit rate BR, inputted to the adaptive initial parameter determining unit 10, whereby adaptive initial parameter...
Cis 1,2,3,4,4a,9,10,10a,-octahydrobenzo[f]quinoline was also obtained according to Synthesis, 494 (1986). Among the compounds of compound (I), the compound wherein j is 1 can be obtained by standard procedures. For example, oxidation of the compound (4') in the above process 3 ...
(f) a C.sub.3-6 cycloalkyl, (g) a C.sub.1-6 alkoxyoptionally having 1 to 3 halogen atoms, (h) a C.sub.1-6 alkylthiooptionally having 1 to 3 halogen atoms, (i) a hydroxyl, (j) an amino, (k)a mono-C.sub.1-6 alkylamino, (1) a di-C.sub.1-6 alkylamino, (m) aC...
I, S, T, L, or W; and the substitution of Y at position 8 is P, L, F, or is not present; and wherein said substitution, addition, or deletion of at least one amino acid residue does not inhibit the ability of said antibody or antigen-binding fragment thereof to bind human CB1...